At TTP, we design and engineer great products, but what sets us apart is our technology development. We disrupt by creating new technology solutions, taking them from concept to prototype all the way through to product engineering and manufacture.
We don’t just design solutions. We make new things happen with technology. From helping people to see, to delivering medication, our technology is in the world, making a difference.
It leverages the customisable platforms, subunits, and fast track development capabilities at TTP to provide an accessible and rapid route to market. This is a seamless approach for companies looking to accelerate the development of their assay to a product for use in diagnostics or research.
Key to this service is the ability for TTP’s team to understand the fundamental steps required to convert lab-based biological processes to a functional low-cost disposable and instrument.
The TTP | desktop biology™ platforms provide a route for fast track conversion to product.
These are designed for simplicity for the end user. With well established biology, 15 months customisation to a trial ready system is viable.
At TTP | desktop biology™ we appreciate that unique solutions are sometimes required and our bespoke service addresses this.
TTP | desktop biology™ provides access to key components for many of the functions of a sample to answer system. For example these include:
Not only does TTP | desktop biology™ provide standard liquid handling - be this direct conversion of tip based steps to Puckdx or microfluidics in Periscope - but also other fluidic control systems address key requirements of future assays such as:
TTP | desktop biology™ leverages the full capability and experience of TTP, a truly collaborative, pioneering and multi-disciplinary team of 350 scientists and engineers. With over 30 years experience in the regulated development of instruments and disposables for diagnostics and life sciences, TTP has the expertise to drive development from fundamental science and theoretical modelling to establishing manufacture augmented by functional and biological testing throughout development.
To watch an animation about Desktop Biology click here or the image on right.
Accelerate your time to market with TTP | desktop biology™.
Your biology. Enabled.
To arrange a meeting or call to discuss please email email@example.com
Gas pumps are typically large, noisy and inefficient compared with a liquid pump, as a lot of energy and effort can be expended in simply compressing the gas. The key TTP innovation was to apply a new acoustic approach to creating a pressure gradient. In place of a traditional cavity that changes volume to create the pressure gradient, the acoustic pump has a fixed cavity.
The pressure gradient is produced through use of an acoustic standing wave in a resonant cavity, with a valve placed at a node or anti-node to control flow.
TTP’s Disc Pump can be a positive or negative pressure pump, and is atypical in that it is small, silent, and non-pulsatile, showing almost no output pressure oscillation.
Medical and consumer health are two sectors that show the greatest demand for this technology, where small size and silent operation mean that products that use pumps (e.g. negative-pressure wound care, inflatable vascular cuffs, blood pressure cuff, respiratory ventilators, CPAP) can take on a completely new form factor; in most cases an ambulatory version can be made.
New spin-out from TTP Group plc will develop, licence and manufacture second generation Disc Pump technology, which has proven applications in medical devices, healthcare, and scientific research.
To find out more visit ttpventus.com
“We see a growing trend towards miniaturisation, portability and discrete operation in markets such as medical devices, diagnostics and electronics driving demand for small, silent, high-performance pumps. Responding to this need with an entirely new technology is very exciting.”
Professor Sir Peter Knight
President of IOP, on presenting the Innovation Award from the Institute of Physics to TTP for developing and commercialising the Disc Pump.
As we age, the lens of the human eye loses elasticity (presbyopia) and reading glasses become a necessity. For those who are already myopic, the onset of presbyopia leaves them with three options: to have two pairs of glasses; a pair of the Benjamin Franklin’s 1784 innovation bifocals; or the updated version of progressive lenses, where the bifocal lens is blended to appear continuous.
With specialist knowledge in optics and ophthalmics, TTP turned its attention to improving these options and invented the cholesteric liquid crystal electronic lens. This technology allows a lens to change focal length electronically; the lens shifts from distance to near vision in milliseconds, at the flick of a switch.
A diffractive lens has an optical power which is defined by the pitch and an efficiency defined by the phase change from the depth of the structure. Combining a cholesteric liquid crystal (nearly independent of polarisation) with the diffractive structure allows the phase change to be switched between zero (no optical power) to 2pi (optical power).
Traditionally, in order to achieve optical power change, you need either to bring about a large increase in refractive index, or a large change in the physical size of the lens.
Our innovation was born of the realisation that by leveraging a small refractive index change with a diffractive lens, we could achieve this power change, revolutionising ophthalmics.
With this world-beating proprietary technology, TTP developed the idea into a product, with the manufacturing process for a start-up business being backed by some of the world’s leading VC funds.
You breathe in. You breathe out. This happens about 20,000 times a day, without a second thought. But if you have cystic fibrosis, chronic asthma, or another respiratory disease, it’s a different story. You may need a regular dose of drugs delivered straight into your lungs, just to keep you alive.
Deep lung penetration requires a highly controlled droplet size — too small and the droplets are exhaled, too large and they’ll land in the back of the throat.
TTP’s challenge was to find a better way to deliver liquid-phase drugs directly into the lungs, one that would increase drug efficacy and eliminate propellant gases.
The solution was TouchSpray™, a chamberless, planar nozzle plate driven by a piezoelectric actuator. The inertial transfer mechanism generates a highly defined aerosol of liquid droplets at the touch of a button.
The invention of this breakthrough technology ultimately led to the global launch of the PARI eFlow® electronic nebuliser — a new inhaler that cuts patient treatment time by an amazing 50%. The drug delivery technology used in the PARI eFlow® electronic nebuliser enables liquid medication to be absorbed through the lungs with as much as 90% efficacy.
Reduces treatment time by more than 50%.
Silent, discreet operation.
Battery-powered and easily portable.
Interchangeable spray heads allow easy cleaning.
More reliable and serviceable than traditional compressor-based systems.
Designed for use with all inhalation medications approved in Europe.
Hopefully these case studies have shown you just a little of what a collaboration with TTP can achieve, from the creation of powerful and ground-breaking new products and solutions, through to their development and manufacture.
We believe it’s a uniquely visionary approach to Technology Development that can help our partners harness – and commercialise – the power of a great idea.
Read more case studies on:
Melbourn Science Park
SG8 6EE UK
Tel: +44 1763 262626
Fax: +44 1763 261582
Registered number: 3304950
Registered office: as shown above
Country of registration: England & Wales
VAT number: 636 9859 76
The Technology Partnership plc is a TTP Group plc company.
© 2017 The Technology Partnership. All rights reserved.